PDF herunterladen
Thromb Haemost 1999; 82(02): 218-225
DOI: 10.1055/s-0037-1615836
Research Article
Schattauer GmbH

Region of Factor IXa Protease Domain that Interacts with Factor VIIIa: Analysis of Select Hemophilia B Mutants

S. Paul Bajaj
1   Departments of Medicine, Pathology, and Biochemistry, Saint Louis University School of Medicine, St. Louis, MO, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
09. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Introduction

The identification of coagulation factor IX as a substance required for blood coagulation was first established by Pavlovsky, who reported that a mixture of blood from two hemophiliacs clotted normally.1 Based on this discovery and subsequent observations,2 hemophilia was divided into two conditions-hemophilia A or factor VIII deficiency, the most prevalent condition, and hemophilia B or factor IX deficiency, a less common condition. Since then, much has been learned about the molecular and structural biology of factor IX. It is a vitamin K-dependent protein that participates in the middle phase of the intrinsic as well as the extrinsic coagulation cascade.3 The gene for factor IX consists of eight exons and seven introns, is approximately 34 kb long, and located on the long arm of the X-chromosome at band Xq27.1.4,5 The positions of the introns in the factor IX gene are essentially identical to those of the other three homologous proteins, namely, factor VII, factor X, and protein C;3 the genes for the latter three proteins, however, are not located on the X-chromosome.

 

  • References

  • 1 Pavlovsky A. Contribution of pathogenesis to hemophilia. Blood 1947; 2: 185-191.
    PubMedGoogle Scholar
  • 2 Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey C, O’Brien JR. Christmas disease, a condition previously mistaken for hemophilia. Br Med J. 1952; 2: 1378-1387.
    CrossrefPubMedGoogle Scholar
  • 3 Davie EW, Fujikawa K, Kiesiel W. The coagulation cascade. Initiation, maintenance and regulation. Biochemistry. 1991; 30: 10363-10370.
    CrossrefPubMedGoogle Scholar
  • 4 Anson DS, Choo KH, Rees DJG, Giannelli F, Gould K, Huddleston JA, Brownlee GG. The gene structure of human antihemophilic factor IX. EMBO J. 1984; 3: 1053-1060.
    PubMedGoogle Scholar
  • 5 Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985; 24: 3736-3750.
    CrossrefPubMedGoogle Scholar
  • 6 Kurachi K, Kurachi S. Regulatory mechanism of the factor IX gene. Thromb Haemost. 1995; 73: 333-339.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Nishimura H, Kawabata S, Kisiel W, Hase S, Ikenaka T, Takao T, Shimonishi Y, Iwanaga S. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Gle) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem. 1989; 264: 20320-20325.
    PubMedGoogle Scholar
  • 8 Nishimura H, Takao T, Hase S, Shimonishi Y, Iwanaga S. Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue. J Biol Chem. 1992; 267: 17520-17525.
    PubMedGoogle Scholar
  • 9 Harris RJ, van Halbeek H, Glushka J, Basa LJ, Ling VT, Smith KJ, Spellman MW. Identification and structural analysis of the tetrasaccharide NeuAc alpha (266) Gal beta (164) GlcNAc beta (163) Fuc alpha 160-linked to serine 61 of human factor IX. Biochemistry. 1993; 32: 6539-6547.
    CrossrefPubMedGoogle Scholar
  • 10 Agarwala KL, Kawabata S, Takao T, Murata H, Shimonishi Y, Nishimura H, Iwanaga S. Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. Biochemistry. 1994; 33: 5167-5171.
    CrossrefPubMedGoogle Scholar
  • 11 DiScipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest. 1978; 61: 1528-1538.
    CrossrefPubMedGoogle Scholar
  • 12 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 1977; 74: 5260-5264.
    CrossrefPubMedGoogle Scholar
  • 13 Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate limiting step in the activation of factor IX by factor Xla and by factor Vlla/tissue factor. Biochemistry. 1983; 22: 4047-4053.
    CrossrefPubMedGoogle Scholar
  • 14 Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem. 1991; 266: 11317-11327.
    PubMedGoogle Scholar
  • 15 Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA. 1995; 92: 9796-9800.
    CrossrefPubMedGoogle Scholar
  • 16 Banner DW, D’Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
    CrossrefPubMedGoogle Scholar
  • 17 Sabharwal AK, Padmanabhan K, Tulinsky A, Mathur A, Gorka J, Bajaj SP. Interaction of calcium with native and decarboxylated human factor X. J Biol Chem. 1997; 272: 22037-22045.
    CrossrefPubMedGoogle Scholar
  • 18 Amphlett GW, Kisiel W, Castellino FJ. The interaction of Ca2+ with human factor IX. Arch Biochem Biophys. 1981; 208: 576-585.
    CrossrefPubMedGoogle Scholar
  • 19 Bajaj SP. Cooperative Ca2+-binding to human factor IX. J Biol Chem. 1982; 257: 4127-4132.
    PubMedGoogle Scholar
  • 20 Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry. 1995; 34: 12126-12137.
    CrossrefPubMedGoogle Scholar
  • 21 Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. The structure of a Ca2+-binding epidermal growth factor-like domain; its role in protein-protein interactions. Cell. 1995; 82: 131-141.
    CrossrefPubMedGoogle Scholar
  • 22 Bajaj SP, Sabharwal AK, Gorka J, Birktoft JJ. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca2+-binding site in the protease domain. Proc Natl Acad Sci USA. 1992; 89: 152-156.
    CrossrefPubMedGoogle Scholar
  • 23 Bajaj SP, Birktoft JJ. Human factor IX and factor IXa. Methods Enzymol. 1993; 222: 96-128.
    PubMedGoogle Scholar
  • 24 Freedman SJ, Blostein MD, Baleja JD, Jacobs M, Furie BC, Furie B. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem. 1996; 271: 16227-16236.
    CrossrefPubMedGoogle Scholar
  • 25 Ahmad SS, Wong MY, Rawala R, Jameson BA, Walsh PN. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry. 1998; 37: 1671-1679.
    CrossrefPubMedGoogle Scholar
  • 26 Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci USA. 1994; 91: 3574-3578.
    CrossrefPubMedGoogle Scholar
  • 27 Lenting PJ, Christophe OD, ter Maat H, Rees JG, Mertens K. Ca2+-binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding. J Biol Chem. 1996; 271: 25332-25337.
    CrossrefPubMedGoogle Scholar
  • 28 Ahmed SS, Rawala R, Cheung WF, Stafford DW, Walsh PN. The role of the second growth-factor domain of human factor IXa in binding to platelets and in factor X activation. Biochem J. 1995; 310: 427-431.
    CrossrefPubMedGoogle Scholar
  • 29 Bajaj SP, Rapaport SI, Maki SL. A monoclonal antibody to factor IX that inhibits the factor VIII potentiation of factor X activation. J Biol Chem. 1985; 260: 11574-11580.
    PubMedGoogle Scholar
  • 30 Astermark J, Hogg PJ, Stenflo J. The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXaβ. Effects on the serine protease module and factor X activation. J Biol Chem. 1994; 269: 3682-3689.
    PubMedGoogle Scholar
  • 31 O’Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem. 1995; 270: 27087-27092.
    CrossrefPubMedGoogle Scholar
  • 32 Frazier D, Smith KJ, Cheung W-F, Ware J, Lin S-W, Thompson AR, Reisner H, Bajaj SP, Stafford DW. Mapping of monoclonal antibodies to human factor IX. Blood 1989; 74: 971-977.
    PubMedGoogle Scholar
  • 33 Ludwig M, Sabharwal AK, Brackmann HH, Olek K, Smith KJ, Birktoft JJ, Bajaj SP. Hemophilia B caused by five different non-deletion mutations in the protease domain of factor IX. Blood 1992; 79: 1225-1232.
    PubMedGoogle Scholar
  • 34 Hamaguchi N, Bajaj SP, Smith KJ, Stafford DW. The role of amino-terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa. Blood 1994; 84: 1837-1842.
    PubMedGoogle Scholar
  • 35 Mathur A, Zhong D, Sabharwal AK, Smith KJ, Bajaj SP. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J Biol Chem. 1997; 272: 23418-23426.
    CrossrefPubMedGoogle Scholar
  • 36 Giannelli F, Green PM, Sommer SS, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res. 1996; 24: 103-118.
    CrossrefPubMedGoogle Scholar
  • 37 Mathur A, Smith KJ, Bajaj SP. Importance of helix-162 (chymotrypsin numbering) of factor IXa in its interaction with factor VIIIa. Protein Sci. 1998; 7 (Suppl. 01) 135.
    PubMedGoogle Scholar
  • 38 Mathur A, Zhong D, Smith KJ, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Blood 1998; 92 (Suppl. 01) 352a.
    PubMedGoogle Scholar
  • 39 Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa: Importance of helix-330 (helix-162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem. 1999; 274: 18477-18486.
    CrossrefPubMedGoogle Scholar
  • 40 Chang J, Jin J, Lollar P, Bode W, Brandstetter H, Hamaguchi N, Straight DL, Stafford DW. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998; 273: 12089-12094.
    CrossrefPubMedGoogle Scholar
  • 41 Rees DJ, Jones IM, Handford PA, Walter SJ, Esnouf MP, Smith KJ, Brownlee GG. The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX. EMBO J. 1988; 7: 2053-2061.
    PubMedGoogle Scholar
  • 42 Hughes PE, Morgan G, Rooney EK, Brownlee GG, Handford P. Tyrosine 69 of the first epidermal growth factor-like domain of human factor IX is essential for clotting activity. J Biol Chem. 1993; 268: 17727-17733.
    PubMedGoogle Scholar
  • 43 Chang JL, Jin JP, Straight DL, Stafford DW. Residues 330-338 in catalytic domain of factor IX represent an interactive site for both factor VIIIa and factor X. Blood 1998; 92 (Suppl. 01) 184a.
    PubMedGoogle Scholar
  • 44 Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J. 1996; 15: 6822-6831.
    CrossrefPubMedGoogle Scholar
  • 45 Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr 1991; A47: 110-119.
    CrossrefPubMedGoogle Scholar
  • 46 Lin S-W, Smith KJ, Welsch D, Stafford DW. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem. 1990; 265: 144-150.
    PubMedGoogle Scholar
  • 47 Chang JY, Monroe DM, Stafford DW, Brinkhous KM, Roberts HR. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest. 1997; 100: 886-892.
    CrossrefPubMedGoogle Scholar
  • 48 McCord DM, Monroe DM, Smith KJ, Roberts HR. Characterization of the functional defect in factor IX Alabama. J Biol Chem. 1990; 265: 10250-10254.
    PubMedGoogle Scholar
  • 49 Spitzer SG, Kuppuswamy MN, Saini R, Kasper CK, Birktoft JJ, Bajaj SP. Factor IXHollywood: Substitution of Pro55 by Ala in the first epidermal growth factor-like domain. Blood 1990; 76: 1530-1537.
    PubMedGoogle Scholar
  • 50 Christophe OD, Lenting PJ, Kolkman JA, Brownlee GG, Mertens K. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain. J Biol Chem. 1998; 237: 222-227.
    PubMedGoogle Scholar
  • 51 Larson PJ, Stanfield-Oakley SA, VanDusen WJ, Kasper CK, Smith KJ, Monroe DM, High KA. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa. J Biol Chem. 1996; 271: 3869-3876.
    CrossrefPubMedGoogle Scholar
  • 52 Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998; 273: 19049-19054.
    CrossrefPubMedGoogle Scholar
  • 53 Bajaj SP, Miletich JP. Unpublished data.
    PubMedGoogle Scholar